ClinicalTrials.gg
Status unknownNCT03413306Updated Mar 15, 2021

Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA

A Phase 3 interventional study of Eltrombopag and IST (ATG + CsA) in Acquired Aplastic Anemia, sponsored by Federal Research Institute of Pediatric Hematology, Oncology and Immunology. Status unknown at 1 site in Russian Federation. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-03-15.

Sponsored by Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Dec 2016, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.

Planned enrollment
2nd of 17
100 · median 36
Started
2016
the only one that year
Phase 3
3 of 17
1 open now
Registered
11th of 17
by date
Lead sponsor
1 of 17
Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 2nd largest by planned enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 11th registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing eltrombopag in Anemia, Aplastic, or all of them as a file.
02

Study summary

The analysis of our own clinical data suggests that majority of the hematologic responses observed after the course of h-ATG/CsA is partial, and about 10% tend to have cyclosporine dependence.

The aim of the current study is to improve the rate and the quality of hematologic response as well as to prevent delayed complications such as relapse and clonal progression by means of adding eltrombopag to standard immunosuppressive therapy

Read the detailed description

This trial will evaluate safety and efficacy of combination eltrombopag with standard hATG/CSA as first line therapy in patients with SAA. The primary endpoint is going to be estimating the rate of complete hematologic response at the point in four months after the end of the treatment. Secondary endpoints are probability of relapse, hematologic blood count recovery in 6 and 12 months after the treatment, survival, clonal evolution into myelodysplasia and leukemia

Aplastic anemia can be treated effectively with allogeneic bone marrow transplantation and immunosuppressive therapy with horse anti-thymocyte globulin (h-ATG) and cyclosporine (CsA), allowing to achieve a comparable long-term survival about 80%. However, one third of the patients treated with h-ATG/CsA, does not respond, and 25-30% of the responders relapse. The analysis of our clinical data suggests that majority of the hematologic responses observed following initial h-ATG/CsA are partial, with only a few patients achieving normal blood counts, and about 10% tend to have cyclosporine dependence. Although horse ATG/CsA provides represented a major advance in the treatment of SAA, such condition as refractory course of the disease, incomplete response, relapse, and clonal evolution limit the success of this treatment. Thus, new regimens are needed to overcome these limitations and provide a better alternative to stem cell transplantation.

One option of improving the quality of hematologic responses is influencing underlying stem cell function. Previous attempts to improve response by hematopoietic cytokines, including erythropoietin and G-CSF, have failed. Thrombopoietin is the principal endogenous regulator of platelet production. In addition, TPO also has stimulatory effects onto primitive multilineage progenitors and stem cells in vitro and animal models. Eltrombopag (Revolade), an oral 2nd generation small molecule TPO-agonist, is approved for treatment of chronic immune thrombocytopenic purpura and SAA who had insufficient response to immunosuppressive therapy. Eltrombopag increases platelets in healthy subjects and in thrombocytopenic patients, and recently has showed clinically significant hematologic responses in refractory SAA patients. The aim of this tudy to improve hematologic response rate and its quality, as well as to prevent late complications such as relapse and clonal progression, by adding eltrombopag into standard immunosuppressive therapy This trial evaluates safety and efficacy of combining eltrombopag with standard hATG/CSA as the first line of therapy in patients with SAA. The primary endpoint is going to be estimation of the rate of complete hematologic response in 4 months. Secondary endpoints are probability of relapse, robust hematologic blood count recovery in 6 and 12 months after the treatment, survival, clonal evolution to myelodysplasia and leukemia.

This is a trial aiming to increase 4 months overall response rate. The sample size is calculated on the hypothesis that the experimental treatment will increase the 4 months response rate in 20% in comparison with standard IST treatment arm. Under these assumptions, the sample size to reject the null hypothesis is n=100 patients, 50 patients in each treatment arm; alpha-error 0.05; power 0.75.

03

Conditions studied

  • Acquired Aplastic Anemia

Browse trials for

Keywords

  • aplastic anemia
  • immunosupressive therapy
  • ATG
  • eltrombopag
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of severe and very severe Aplastic anemia
  2. 2 - 18 years old
  3. Written signed by a parent or legal guardian prior to initiation of any study specific procedure.
  4. Absence of HLA-identical family member

Exclusion criteria

Exclusion Criteria:

  1. myelodysplastic syndrome 4. Prior therapy 5. Patients with hepatic, renal or cardiac failure, or any other life- threatening concurrent disease 6. to any of the component medications 7. Creatinine >2.5 mg/dL× the , 8. Total >1.5 × the upper limit of normal mg/dL , 9. (AST) or alanine aminotransferase (ALT) >3-5 × the upper limit of normal
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Eltrombopag + IST (ATG + CsA)

    Drug: Eltrombopag · Drug: IST (ATG + CsA)

  • Active comparator
    IST (ATG + CsA)

    Drug: IST (ATG + CsA)

Interventions

  • Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.

    Also known as: Revolade

  • DrugIST (ATG + CsA)

    Also known as: controle

06

What researchers measure

Primary outcomes

  1. ORR (CR + PR)

    The primary objective of this trial is to investigate whether Eltrombopag added to standard immunosupressive treatment hATG and CsA increases the overal (partial + complete) response rate at four months in untreated children with severe aquired aplastic anemia.

    Time frame: 4 months

Secondary outcomes

  1. Platelet count

    Time frame: 4 and 6 months

  2. Hemoglobin

    Time frame: 4 and 6 months

  3. Neutrophil count

    Time frame: 4 and 6 months

  4. Cumulative incidence of response

    Time frame: 4 and 6 months

  5. Duration of hematologic response

    Time from the date of the start of response to the date of relapse defined as again meeting criteria for severe or moderate aplastic anemia

    Time frame: 2 years

  6. Overall survival

    Time frame: 2 years

  7. Event-free survival

    Time frame: 2 years

  8. Cumulative incidence of relapse

    Time frame: 2 years

  9. Cumulative incidences of clonal evolution

    Time frame: 2 years

  10. Cumulative incidence of PNH population occurrence and clinical hemolytic PNH occurrence

    Time frame: 2 years

  11. Cumulative incidence of adverce effects

    Number of participants with severe adverse events (3-5 stage CTCAE v.4.0) associated with assessment of eltrombopag usage in patients with severe aplastic anemia in 4 months after first day of treatment. Death before evidence of adverce event is competing event.

    Time frame: 4 months

  12. Cumulative incidence of adverce effects

    Number of participants with severe adverse events (3-5 stage CTCAE v.4.0) associated with assessment of eltrombopag dose in patients with severe aplastic anemia in 4 months after first day of treatment. Death before evidence of adverce event is competing event.

    Time frame: 4 months

  13. Comparison of cumulative incidence of adverce effects in two arms

    comparison between two arms of number of participants with severe adverse events (3-5 stage CTCAE v.4.0) associated with treatment in patients with severe aplastic anemia in 2 years after first day of treatment with death before evidence of adverce event as a competing event.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
    Moscow, 117198, Russian Federation
    Recruiting
08

References and documents

Publications

  • Goronkova O, Novichkova G, Salimova T, Kalinina I, Baidildina D, Petrova U, Antonova K, Sadovskaya M, Suntsova E, Evseev D, Matveev V, Venyov D, Khachatryan L, Litvinov D, Pshonkin A, Ovsyannikova G, Kotskaya N, Gobadze D, Olshanskaya Y, Popov A, Raykina E, Mironenko O, Voronin K, Purbueva B, Boichenko E, Dinikina Y, Guseynova E, Sherstnev D, Kalinina E, Mezentsev S, Streneva O, Yudina N, Plaksina O, Erega E, Maschan M, Maschan A. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. Blood Adv. 2023 Mar 28;7(6):953-962. doi: 10.1182/bloodadvances.2021006716. PubMed 35446936 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2016 (actual). Primary completion is estimated for Oct 2022, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2017
First posted
Jan 29, 2018
StartActual
Dec 10, 2016
Primary completionEst.
Oct 20, 2022
CompletionEst.
Oct 20, 2022
Last update
Mar 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03413306
Lead sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Responsible party
Sponsor
First posted
Jan 29, 2018
Start date
Dec 10, 2016
Primary completion
Oct 20, 2022 (estimated)
Completion
Oct 20, 2022 (estimated)
Last update
Mar 15, 2021

Study contacts

Olga Goronkova, MD
Contact
goronkova@yandex.ru
+7-495-287-65-70 ext. 5527
Galina Novichkova
principal investigator · Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
Alexei Maschan
principal investigator · Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion